Are psychiatric disorders associated with thyroid hormone therapy in adolescents and young adults with type 1 diabetes?

Abstract

Background: To evaluate the association between thyroid autoimmunity and psychiatric disorders (depression, anxiety, eating disorder, schizophrenia or attention-deficit/hyperactivity disorder) among adolescents and young adults with type 1 diabetes (11-25 years). Methods: We compared 9368 type 1 diabetes patients with thyroid autoimmunity (3789 of them treated with levothyroxine) with 62 438 type 1 diabetes patients without any thyroid disease from a multicentre diabetes patient follow-up registry (DPV) in terms of psychiatric disorders. Thyroid autoimmunity was defined as documented diagnosis of Hashimoto thyroiditis or positive antibodies against thyroid peroxidase or thyroglobulin. Multivariable logistic regression models were used to calculate odds ratios for the respective psychiatric disorders in type 1 diabetes patients with thyroid autoimmunity (overall and stratified by levothyroxine therapy) compared to type 1 diabetes patients without thyroid diseases (reference).

Advance in the Correlation between Diabetic Nephropathy and Abnormal Serum Thyroid Hormone Levels in Patients

“…A new thyroid feedback quantile index (TFQI), an indicator of decreased TH sensitivity, was found to correlate population variation with DM and hypertension in people with normal thyroid function. Eckert et al [ 34 ] evaluated the relationship between thyroid autoimmunity in adolescents and young adults with type 1 DM and found that thyroid function was substantially suppressed in patients with DM. There is a certain relationship between thyroid function and DM.…”

An Eluate of the Medicinal Plant Garcinia kola Displays Strong Antidiabetic and Neuroprotective Properties in Streptozotocin-Induced Diabetic Mice

“…T1D encompasses severe microvascular complications such as cognitive and motor dysfunctions, which are particularly common in pediatric populations and young adults [ 3 – 5 ]. Disorders such as early behavioral alterations, which predict later psychiatric morbidity in one-third of cases in patients [ 6 – 8 ], are common in streptozotocin (STZ)-injected murine models [ 9 – 11 ]. Evidence from epidemiological, clinical, and experimental studies suggests that these complications emerge mainly from inappropriate glycemic control, a puzzling issue also associated with several other complications of T1D, higher hospitalization costs, and higher mortality [ 12 , 13 ].…”